Mr. Matin previously worked for Spectranetics starting in 2007, serving as its Chief Operating Officer from 2014 until its acquisition by Royal Philips in 2017. Before joining Spectranetics, Mr. Matin worked for the Guidant Corporation (now Boston Scientific Corporation) in various commercial and engineering roles from 1997 until 2007. Mr. Matin graduated from Harvard Business School with a Master in Business Administration, and graduated from the University of California, Berkeley with honors with a Bachelor of Science in Mechanical Engineering.
Mr. Grossman previously served as the President, Chief Executive Officer and Director for Thoratec Corporation through its $3.4 billion acquisition by St. Jude Medical (now Abbott Laboratories, NYSE: ABT) in 2016. From 2011 to 2013, Mr. Grossman served as President, Chief Executive Officer and Director for Conceptus, Inc., where he led its turnaround and acquisition by Bayer Healthcare in 2013. From 2007 to 2011, Mr. Grossman served as a Managing Director with the Texas Pacific Group, a private equity firm, in their healthcare investment team. Mr. Grossman currently serves as a director for Vyaire, Inc., Outset Medical, Inc. and Therox, Inc., and has previously served as a director for Thoratec Corporation, Conceptus, Inc., ZELTIQ Aesthetics, Inc., Intuitive Surgical, Inc., Kyphon, Inc. and a number of privately held medical device companies. Mr. Grossman received a Bachelor of Science in Life Sciences from the Ohio State University and a Master in Business Administration from Pepperdine University.
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology helping to transform radiation therapy, resulting in improved treatment outcomes that benefit both patients and health care systems around the world. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
SOURCE ViewRay, Inc.
Back to HCB News
